Spectrum of malignancies in Jaipur region (2004-2008)

Sharma, Reetika; Kapoor, Rakesh; Ba, Bang; Gurjar, K.

doi:10.4103/0019-509x.134624

Cited by 8 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Histopathological analysis of uterine corpus cancer revealed adenocarcinoma in 79% cases followed by squamous cell carcinoma and malignant mixed mullerian tumor. This was similar to the findings of Sharma RG et al 5 Gastrointestinal System: Gastrointestinal cancer was the second most common organ system accounting for 14% of thecases with mean age of 55 years. Colon and rectum was the most frequent site followed by esophagus, gastric and anal canal (Table 1).…”

Section: Resultssupporting

confidence: 91%

“…IHC studies of 162 breast malignancy cases showed majority to be luminal type (63%) followed by HER2 rich (19%) and triple negative cancers (18%).Ghosh J et al, in 2011, observed 51.2% breast cancers to be Luminal type, 29.8% were Triple negative and 19% were HER2 rich. 14 Reproductive System: Majority of the reproductive system malignancies involved cervix followed by ovaries and uterine corpus which is also corroborated by a study by Sharma RG et al 5 Cervical malignancies in our study group had a mean age of 52 years. Gumpeny N. et al in Visakhapatnam, Andhra Pradesh, India, observed maximum number of cases (29%) between 41 and 50 years of age.…”

Section: Resultssupporting

confidence: 88%

“…Sharma MK et al, reported breast to be the commonest site for female malignancies accounting for 33.3% of the cases. 3,5 Agarwal KH and Rajderkar SS studied 941 cases of female cancers in Miraj, Maharashtra and reported cervix (22.1%) to be the commonest site followed by breast (13.1%). 6 According to the WHO, the breast is the commonest site for malignancy among females, globally.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Recent trends in histopathological spectrum of malignancies among females in western Maharashtra

Gore¹,

Dey²,

Kumar³

et al. 2020

IJPO

View full text Add to dashboard Cite

Introduction: Aim of this study is to evaluate the histopathological spectrum of female malignancies with a motive to understand the prevalent trends of this complex disease. Materials and Methods: This was a retrospective and prospective study carried over a period of three years. All female patients with histopathologically confirmed malignancies were included in the study. Result: Total of 1016 cases of malignant lesions were included of which majority were in age group of 40 to 69 years. Breast was the commonest site for primary malignancies followed by cervix. Oropharyngeal squamous cell carcinoma ranked third while colorectal carcinomas emerged as the fourth most prevalent malignancy followed by ovarian cancer. Infiltrating duct carcinoma of the breast was the commonest histopathologic type of malignancy. Majority of the cervical and oropharyngeal cancers were squamous cell type. Colorectal adenocarcinoma was the most common malignancy in the GI tract. Among skin malignancies, squamous cell carcinoma were the most prevalent type followed by basal cell carcinoma and malignant melanoma. Adenocarcinomas were the commonest lung lesions while papillary carcinoma was the most prevalent thyroid malignancy. Transitional cell cancers were the most frequent urinary bladder lesions while renal cell carcinomas were most common kidney malignancy. Conclusion:In spite of many recently developed diagnostic modalities; histopathological examination remains the gold standard for the diagnosis of malignant lesions. Hospital based Cancer Registries should be established since they provide data which can prove to be an invaluable tool to understand and plan effective remedial measures in the battle against cancer.

show abstract

Section: Resultssupporting

confidence: 91%

Section: Resultssupporting

confidence: 88%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Recent trends in histopathological spectrum of malignancies among females in western Maharashtra

Gore¹,

Dey²,

Kumar³

et al. 2020

IJPO

View full text Add to dashboard Cite

show abstract

“…Sharma et al ., in their review titled “Spectrum of malignancies in Jaipur region (2004–2008)” observed that head and neck cancers formed the single largest group in their study (17.96% of all cancers) with majority (81%) of these cancers found in male patients with M:F ratio of 4.26:1. [ 1 ] Similar results in our study suggest that this high frequency of these cancers among male population is probably because of the increased use of tobacco products. The highest prevalence by site of oral and oropharyngeal cancers can again be linked to increased use of tobacco products.…”

Section: Discussionsupporting

confidence: 88%

“…In context to Jaipur city, head and neck cancers form the single largest group of cancers constituting 17.96% of all cancers with majority (81%) of these cancers found in male patients with a M:F ratio of 4.26:1. [ 1 ] Approximately half to three-fourths of cases of SCCHN present in locally advanced (LA) stage. Neoadjuvant chemotherapy in this subset of patients has been proven to increase progression-free survival and overall survival and is now the standard of care.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study

Mathur

Rastogi

Gurjar

et al. 2018

South Asian J Cancer

View full text Add to dashboard Cite

Background:Squamous cell carcinoma of head and neck (SCCHN) is one of the most common cancers seen in India and also the world. Majority of patients present in locally advanced (LA) disease where neoadjuvant combination chemotherapy with a taxane plus platinum with/without 5-Fluorouracil is the standard of care treatment. There are no/few prospective trials of weekly paclitaxel in SCCHN in spite of convincing evidence regarding safety and tolerability in other solid tumors such as breast, ovary, and lung carcinoma. In the present study, we prospectively assessed the safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with LA-SCCHN.Materials and Methods:We included 50 newly diagnosed patients of LA-SCCHN in the study and randomized them into two groups to receive either low-dose weekly (80 mg/sq. m) or standard three-weekly (175 mg/sq. m) paclitaxel along with standard dose carboplatin (AUC 5) and assessed response rates and toxicities.Results:Age and sex were evenly matched in both groups. Oral and oropharyngeal cancers were the most common sites. Hematological toxicities were significantly more in the three-weekly group. Nonhematological toxicities, especially neuropathy, were also more in this group. The overall response rate (complete response + partial response) in the three-weekly arm was 36% versus 52% in the weekly arm.Conclusion:Data from our small study suggest that weekly paclitaxel plus platinum neoadjuvant chemotherapy may be superior to the standard every 3 weeks’ administration in terms of safety as well as efficacy in patients with LA-SCCHN.

show abstract

Epidemiological and Histopathological Analysis of Head and Neck Cancers in Northern India- A Retrospective Review

Lakhera,

Kumar,

Singhal

et al. 2023

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Spectrum of malignancies in Jaipur region (2004-2008)

Cited by 8 publications

References 0 publications

Recent trends in histopathological spectrum of malignancies among females in western Maharashtra

Recent trends in histopathological spectrum of malignancies among females in western Maharashtra

Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study

Epidemiological and Histopathological Analysis of Head and Neck Cancers in Northern India- A Retrospective Review

Contact Info

Product

Resources

About